Table 1.
Patient characteristics.
| Characteristics | Patients |
|---|---|
| Number of patients, n | 28 |
| Gender (male/female), n (%) | 15 (53.6%)/13 (46.4%) |
| Age (years), mean±SD; min.-max. | 56.8 ± 12.6; 27–85 |
| BMI (kg/m2), mean±SD; min.-max. | 27.7 ± 5.2; 17.2–28.6 |
| Child-Pugh grade (A/B/C), n (%) | 7 (25.0%)/11 (39.3%)/10 (35.7%) |
| MELD score, mean±SD; min.-max. | 10.5 ± 2.8; 7–8 |
| ASA class (I/II/III/IV), n (%) | 0 (0%)/9 (32.1%)/17 (60.7%)/2 (7.2%) |
| Preoperative serum GPT/ALT level (IU/L), mean±SD | 135.7 ± 12.4 |
| Preoperative serum GOT1/AST level (IU/L), mean±SD | 213.4 ± 18.0 |
| Preoperative serum ALPL level (IU/L), mean±SD | 386.3 ± 38.2 |
| Preoperative serum TBIL level (μmol/L), mean±SD | 46.8 ± 14.4 |
| Preoperative serum GGT1 level (IU/L), mean±SD | 85.6 ± 18.7 |
| Preoperative serum ALB level (g/L), mean±SD | 23.7 ± 5.3 |
| Preoperative serum IGH level (g/L), mean±SD | 54.6 ± 7.4 |
| Origin of cirrhosis, n (%) | |
| HBV infection | 8 (28.6%) |
| HCV infection | 2 (7.1%) |
| Alcohol consumption | 7 (25.0%) |
| HBV infection plus alcohol consumption | 4 (14.3%) |
| NAFLD/NASH | 6 (21.4%) |
| Hereditary hemochromatosis | 1 (3.6%) |
Abbreviations: BMI, body mass index; MELD, model for end-stage liver disease; ASA, American Society of Anesthesiologists; GPT/ALT, glutamic–pyruvic transaminase; GOT1/AST, glutamic-oxaloacetic transaminase 1; ALPL, alkaline phosphatase; TBIL, total bilirubin; GGT1, gamma-glutamyltransferase 1; ALB, albumin; IGH, immunoglobulin heavy; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis. Quantitative values were expressed as means with standard deviations or medians with range, while categorical values were expressed as numbers with percentages.